 |
市場調査レポート
商品コード
1462787
アレルギー免疫療法の2030年までの市場予測：タイプ別、アレルギータイプ別、流通チャネル別、エンドユーザー別、地域別の世界分析Allergy Immunotherapy Market Forecasts to 2030 - Global Analysis By Type, Allergy Type, Distribution Channel, End User and By Geography |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。
| アレルギー免疫療法の2030年までの市場予測：タイプ別、アレルギータイプ別、流通チャネル別、エンドユーザー別、地域別の世界分析 |
|
出版日: 2024年04月04日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 図表
- 目次
Stratistics MRCによると、アレルギー免疫療法の世界市場は2023年に26億7,000万米ドルを占め、予測期間中にCAGR 11.6％で成長し、2030年には57億7,000万米ドルに達すると予測されています。
アレルギー免疫療法は、アレルギー注射や減感作療法としても知られ、花粉症、喘息、食物アレルギーなどのアレルギーの治療法です。免疫系を徐々に増加するアレルゲンにさらし、過剰反応しないように再教育し、アレルギー症状を引き起こすことで効果を発揮します。症状を管理するだけの薬物療法とは異なり、免疫療法は長期的な解決、あるいは治癒の可能性さえあるため、慢性アレルギーの緩和を求める人々にとって有望なアプローチであり、それによって患者のQOLを向上させ、対症療法的な薬物療法への依存を減らすことができます。
米国アレルギー喘息免疫学会の推計によると、18歳以上のアメリカ人口の約7.8％がアレルギー性鼻炎を発症しています。
アレルギーの有病率の上昇
喘息、花粉症、食物過敏症などのアレルギーを発症する人が増えるにつれ、単に症状を管理するだけでなく、長期的な解決策に対する需要が高まっています。アレルギー免疫療法は、アレルゲンに対する免疫系を徐々に減感作することで、アレルギーを完治させる可能性のあるユニークなアプローチを提供します。このような恒久的な解決策へのニーズの高まりは、アレルギー患者の人口増加と相まって、免疫療法治療を開発・提供する企業にとって大きな市場機会を生み出しています。
治療コスト
アレルゲンの抽出、医師の診察、副作用のモニタリングにかかる費用は相当なものになります。この経済的負担により、特に十分な経済的余裕のない患者にとっては、免疫療法へのアクセスが制限される可能性があります。また、長期にわたる治療と継続的な経過観察の必要性が、全体的な費用の負担を大きくし、この有益な治療法を求める患者にとって障壁となっています。
個別化医療への注目の高まり
個別化医療への注目の高まりは、アレルギー免疫療法市場にとって重要な機会です。個々の患者のアレルギー体質（誘因、年齢、既往歴などの要因を考慮）に合わせた治療計画を立てることで、個別化免疫療法は有効性の向上と安全性の改善が期待できます。このような標的を絞ったアプローチにより、効果や副作用への懸念から躊躇していた多くの患者にとって免疫療法がより魅力的なものとなり、最終的に市場の大幅な拡大につながる可能性があります。
代替治療の選択肢
抗ヒスタミン薬やコルチコステロイドなどの薬物療法は、回避策とともに免疫療法と競合します。これらの代替療法は、利便性や安全性の高さから患者やヘルスケアプロバイダーに好まれる可能性があります。このため、免疫療法の市場浸透率や採用率が脅かされ、医療提供者の収益源に影響を与え、市場全体の成長性が制限される可能性があります。
COVID-19の影響
当初は、相互作用の可能性や医療アクセスの制限に対する懸念から、治療開始の遅れや、接触を最小限に抑えるために舌下免疫療法（舌の下に投与する方法）へのシフトといった混乱が生じた。しかし、パンデミックはアレルギーのような慢性疾患の管理の重要性を浮き彫りにし、将来的には免疫療法のような長期的なソリューションに対する需要の増加につながる可能性もあります。
予測期間中、食物アレルギー分野が最大となる見込み
食物アレルギー分野が最大のシェアを占めると推定されます。食物アレルギーの免疫療法は、免疫系を脱感作してアレルギー反応の重症度を軽減することを目的として、アレルゲンとなる食物を徐々に体内に曝露していくものです。この標的を絞ったアプローチは、単なる症状管理とは異なり、食物アレルギーの治癒の可能性を提供し、多くの患者にとって魅力的な選択肢となります。食物アレルギーがより一般的になるにつれて、この分野は大きな成長が見込まれます。
予測期間中、小売薬局セグメントのCAGRが最も高くなると予想される
小売薬局セグメントは、予測期間中に有利な成長が見込まれます。小売薬局では、免疫療法治療に必要な様々なアレルゲンエキス、医薬品、消耗品を在庫しています。小売薬局の薬剤師は、免疫療法を受ける患者にカウンセリング、教育、サポートを提供し、適切な投与、副作用のモニタリング、治療アドヒアランスの最適化を図っています。小売薬局はその存在感とアクセスの良さから、アレルギー免疫療法への患者のアクセスを拡大し、患者の転帰と満足度を向上させる上で重要な役割を果たしています。
最もシェアの高い地域
アジア太平洋地域は、アレルギーの有病率の増加、可処分所得の増加、新興国市場における大手製薬企業の存在感などから、予測期間中に最大の市場シェアを獲得しました。これらの企業は、舌下免疫療法やアレルゲンの標準化の改善のような進歩に投資しており、治療をより身近で効率的なものにしています。このことは、アレルギー管理に対する意識の高まりと相まって、アジア太平洋地域をアレルギー免疫療法市場の主要な成長エンジンとして位置づけています。
CAGRが最も高い地域：
北米は、アレルギーの有病率の高さ、治療オプションとしての免疫療法に対する社会的認知度の高さ、アクセスを容易にする強固なヘルスケアインフラを背景に、予測期間中に収益性の高い成長が見込まれます。さらに、北米はアレルギー免疫療法の研究開発の温床となっており、常に革新的な治療法が導入されています。
無料のカスタマイズサービス
本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：
- 企業プロファイル
- 追加市場プレーヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
- 地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
- 競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング
目次
第1章 エグゼクティブサマリー
第2章 序文
- 概要
- ステークホルダー
- 調査範囲
- 調査手法
- データマイニング
- データ分析
- データ検証
- 調査アプローチ
- 調査情報源
- 1次調査情報源
- 2次調査情報源
- 前提条件
第3章 市場動向分析
- 促進要因
- 抑制要因
- 機会
- 脅威
- エンドユーザー分析
- 新興市場
- COVID-19の影響
第4章 ポーターのファイブフォース分析
- 供給企業の交渉力
- 買い手の交渉力
- 代替品の脅威
- 新規参入業者の脅威
- 競争企業間の敵対関係
第5章 世界のアレルギー免疫療法市場：タイプ別
- 舌下免疫療法
- 皮下免疫療法
- 特異的免疫療法
第6章 世界のアレルギー免疫療法市場：アレルギータイプ別
- アレルギー性喘息
- アレルギー性鼻炎
- アトピー性皮膚炎
- 食物アレルギー
- その他のアレルギータイプ
第7章 世界のアレルギー免疫療法市場：流通チャネル別
- 病院薬局
- オンライン薬局
- 小売薬局
第8章 世界のアレルギー免疫療法市場：エンドユーザー別
- 病院
- クリニック
- 診断センター
第9章 世界のアレルギー免疫療法市場：地域別
- 北米
- 米国
- カナダ
- メキシコ
- 欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
- アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
- 南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
- 中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ
第10章 主な発展
- 契約、パートナーシップ、コラボレーション、合弁事業
- 買収と合併
- 新製品発売
- 事業拡大
- その他の主要戦略
第11章 企業プロファイリング
- ALK Abello
- Allergy Therapeutics
- Stallergenes Greer
- Mylan N.V.
- Arrayit Corporation
- Merck KGaA
- Biomay AG
- HollisterStier Allergy
- HAL Allergy Group
- ASIT Biotech
- LETIPharma
- Dermapharm Holding SE
- Carcassia
- Anergis
- DVB Technologies SA
- Adamis Pharmaceuticals Corporation
List of Tables
- Table 1 Global Allergy Immunotherapy Market Outlook, By Region (2021-2030) ($MN)
- Table 2 Global Allergy Immunotherapy Market Outlook, By Type (2021-2030) ($MN)
- Table 3 Global Allergy Immunotherapy Market Outlook, By Sublingual Immunotherapy (2021-2030) ($MN)
- Table 4 Global Allergy Immunotherapy Market Outlook, By Subcutaneous Immunotherapy (2021-2030) ($MN)
- Table 5 Global Allergy Immunotherapy Market Outlook, By Specific Immunotherapy (2021-2030) ($MN)
- Table 6 Global Allergy Immunotherapy Market Outlook, By Allergy Type (2021-2030) ($MN)
- Table 7 Global Allergy Immunotherapy Market Outlook, By Allergic Asthma (2021-2030) ($MN)
- Table 8 Global Allergy Immunotherapy Market Outlook, By Allergic Rhinitis (2021-2030) ($MN)
- Table 9 Global Allergy Immunotherapy Market Outlook, By Atopic Dermatitis (2021-2030) ($MN)
- Table 10 Global Allergy Immunotherapy Market Outlook, By Food Allergy (2021-2030) ($MN)
- Table 11 Global Allergy Immunotherapy Market Outlook, By Other Allergy Types (2021-2030) ($MN)
- Table 12 Global Allergy Immunotherapy Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 13 Global Allergy Immunotherapy Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
- Table 14 Global Allergy Immunotherapy Market Outlook, By Online Pharmacy (2021-2030) ($MN)
- Table 15 Global Allergy Immunotherapy Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
- Table 16 Global Allergy Immunotherapy Market Outlook, By End User (2021-2030) ($MN)
- Table 17 Global Allergy Immunotherapy Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 18 Global Allergy Immunotherapy Market Outlook, By Clinics (2021-2030) ($MN)
- Table 19 Global Allergy Immunotherapy Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
- Table 20 North America Allergy Immunotherapy Market Outlook, By Country (2021-2030) ($MN)
- Table 21 North America Allergy Immunotherapy Market Outlook, By Type (2021-2030) ($MN)
- Table 22 North America Allergy Immunotherapy Market Outlook, By Sublingual Immunotherapy (2021-2030) ($MN)
- Table 23 North America Allergy Immunotherapy Market Outlook, By Subcutaneous Immunotherapy (2021-2030) ($MN)
- Table 24 North America Allergy Immunotherapy Market Outlook, By Specific Immunotherapy (2021-2030) ($MN)
- Table 25 North America Allergy Immunotherapy Market Outlook, By Allergy Type (2021-2030) ($MN)
- Table 26 North America Allergy Immunotherapy Market Outlook, By Allergic Asthma (2021-2030) ($MN)
- Table 27 North America Allergy Immunotherapy Market Outlook, By Allergic Rhinitis (2021-2030) ($MN)
- Table 28 North America Allergy Immunotherapy Market Outlook, By Atopic Dermatitis (2021-2030) ($MN)
- Table 29 North America Allergy Immunotherapy Market Outlook, By Food Allergy (2021-2030) ($MN)
- Table 30 North America Allergy Immunotherapy Market Outlook, By Other Allergy Types (2021-2030) ($MN)
- Table 31 North America Allergy Immunotherapy Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 32 North America Allergy Immunotherapy Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
- Table 33 North America Allergy Immunotherapy Market Outlook, By Online Pharmacy (2021-2030) ($MN)
- Table 34 North America Allergy Immunotherapy Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
- Table 35 North America Allergy Immunotherapy Market Outlook, By End User (2021-2030) ($MN)
- Table 36 North America Allergy Immunotherapy Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 37 North America Allergy Immunotherapy Market Outlook, By Clinics (2021-2030) ($MN)
- Table 38 North America Allergy Immunotherapy Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
- Table 39 Europe Allergy Immunotherapy Market Outlook, By Country (2021-2030) ($MN)
- Table 40 Europe Allergy Immunotherapy Market Outlook, By Type (2021-2030) ($MN)
- Table 41 Europe Allergy Immunotherapy Market Outlook, By Sublingual Immunotherapy (2021-2030) ($MN)
- Table 42 Europe Allergy Immunotherapy Market Outlook, By Subcutaneous Immunotherapy (2021-2030) ($MN)
- Table 43 Europe Allergy Immunotherapy Market Outlook, By Specific Immunotherapy (2021-2030) ($MN)
- Table 44 Europe Allergy Immunotherapy Market Outlook, By Allergy Type (2021-2030) ($MN)
- Table 45 Europe Allergy Immunotherapy Market Outlook, By Allergic Asthma (2021-2030) ($MN)
- Table 46 Europe Allergy Immunotherapy Market Outlook, By Allergic Rhinitis (2021-2030) ($MN)
- Table 47 Europe Allergy Immunotherapy Market Outlook, By Atopic Dermatitis (2021-2030) ($MN)
- Table 48 Europe Allergy Immunotherapy Market Outlook, By Food Allergy (2021-2030) ($MN)
- Table 49 Europe Allergy Immunotherapy Market Outlook, By Other Allergy Types (2021-2030) ($MN)
- Table 50 Europe Allergy Immunotherapy Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 51 Europe Allergy Immunotherapy Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
- Table 52 Europe Allergy Immunotherapy Market Outlook, By Online Pharmacy (2021-2030) ($MN)
- Table 53 Europe Allergy Immunotherapy Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
- Table 54 Europe Allergy Immunotherapy Market Outlook, By End User (2021-2030) ($MN)
- Table 55 Europe Allergy Immunotherapy Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 56 Europe Allergy Immunotherapy Market Outlook, By Clinics (2021-2030) ($MN)
- Table 57 Europe Allergy Immunotherapy Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
- Table 58 Asia Pacific Allergy Immunotherapy Market Outlook, By Country (2021-2030) ($MN)
- Table 59 Asia Pacific Allergy Immunotherapy Market Outlook, By Type (2021-2030) ($MN)
- Table 60 Asia Pacific Allergy Immunotherapy Market Outlook, By Sublingual Immunotherapy (2021-2030) ($MN)
- Table 61 Asia Pacific Allergy Immunotherapy Market Outlook, By Subcutaneous Immunotherapy (2021-2030) ($MN)
- Table 62 Asia Pacific Allergy Immunotherapy Market Outlook, By Specific Immunotherapy (2021-2030) ($MN)
- Table 63 Asia Pacific Allergy Immunotherapy Market Outlook, By Allergy Type (2021-2030) ($MN)
- Table 64 Asia Pacific Allergy Immunotherapy Market Outlook, By Allergic Asthma (2021-2030) ($MN)
- Table 65 Asia Pacific Allergy Immunotherapy Market Outlook, By Allergic Rhinitis (2021-2030) ($MN)
- Table 66 Asia Pacific Allergy Immunotherapy Market Outlook, By Atopic Dermatitis (2021-2030) ($MN)
- Table 67 Asia Pacific Allergy Immunotherapy Market Outlook, By Food Allergy (2021-2030) ($MN)
- Table 68 Asia Pacific Allergy Immunotherapy Market Outlook, By Other Allergy Types (2021-2030) ($MN)
- Table 69 Asia Pacific Allergy Immunotherapy Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 70 Asia Pacific Allergy Immunotherapy Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
- Table 71 Asia Pacific Allergy Immunotherapy Market Outlook, By Online Pharmacy (2021-2030) ($MN)
- Table 72 Asia Pacific Allergy Immunotherapy Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
- Table 73 Asia Pacific Allergy Immunotherapy Market Outlook, By End User (2021-2030) ($MN)
- Table 74 Asia Pacific Allergy Immunotherapy Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 75 Asia Pacific Allergy Immunotherapy Market Outlook, By Clinics (2021-2030) ($MN)
- Table 76 Asia Pacific Allergy Immunotherapy Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
- Table 77 South America Allergy Immunotherapy Market Outlook, By Country (2021-2030) ($MN)
- Table 78 South America Allergy Immunotherapy Market Outlook, By Type (2021-2030) ($MN)
- Table 79 South America Allergy Immunotherapy Market Outlook, By Sublingual Immunotherapy (2021-2030) ($MN)
- Table 80 South America Allergy Immunotherapy Market Outlook, By Subcutaneous Immunotherapy (2021-2030) ($MN)
- Table 81 South America Allergy Immunotherapy Market Outlook, By Specific Immunotherapy (2021-2030) ($MN)
- Table 82 South America Allergy Immunotherapy Market Outlook, By Allergy Type (2021-2030) ($MN)
- Table 83 South America Allergy Immunotherapy Market Outlook, By Allergic Asthma (2021-2030) ($MN)
- Table 84 South America Allergy Immunotherapy Market Outlook, By Allergic Rhinitis (2021-2030) ($MN)
- Table 85 South America Allergy Immunotherapy Market Outlook, By Atopic Dermatitis (2021-2030) ($MN)
- Table 86 South America Allergy Immunotherapy Market Outlook, By Food Allergy (2021-2030) ($MN)
- Table 87 South America Allergy Immunotherapy Market Outlook, By Other Allergy Types (2021-2030) ($MN)
- Table 88 South America Allergy Immunotherapy Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 89 South America Allergy Immunotherapy Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
- Table 90 South America Allergy Immunotherapy Market Outlook, By Online Pharmacy (2021-2030) ($MN)
- Table 91 South America Allergy Immunotherapy Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
- Table 92 South America Allergy Immunotherapy Market Outlook, By End User (2021-2030) ($MN)
- Table 93 South America Allergy Immunotherapy Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 94 South America Allergy Immunotherapy Market Outlook, By Clinics (2021-2030) ($MN)
- Table 95 South America Allergy Immunotherapy Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
- Table 96 Middle East & Africa Allergy Immunotherapy Market Outlook, By Country (2021-2030) ($MN)
- Table 97 Middle East & Africa Allergy Immunotherapy Market Outlook, By Type (2021-2030) ($MN)
- Table 98 Middle East & Africa Allergy Immunotherapy Market Outlook, By Sublingual Immunotherapy (2021-2030) ($MN)
- Table 99 Middle East & Africa Allergy Immunotherapy Market Outlook, By Subcutaneous Immunotherapy (2021-2030) ($MN)
- Table 100 Middle East & Africa Allergy Immunotherapy Market Outlook, By Specific Immunotherapy (2021-2030) ($MN)
- Table 101 Middle East & Africa Allergy Immunotherapy Market Outlook, By Allergy Type (2021-2030) ($MN)
- Table 102 Middle East & Africa Allergy Immunotherapy Market Outlook, By Allergic Asthma (2021-2030) ($MN)
- Table 103 Middle East & Africa Allergy Immunotherapy Market Outlook, By Allergic Rhinitis (2021-2030) ($MN)
- Table 104 Middle East & Africa Allergy Immunotherapy Market Outlook, By Atopic Dermatitis (2021-2030) ($MN)
- Table 105 Middle East & Africa Allergy Immunotherapy Market Outlook, By Food Allergy (2021-2030) ($MN)
- Table 106 Middle East & Africa Allergy Immunotherapy Market Outlook, By Other Allergy Types (2021-2030) ($MN)
- Table 107 Middle East & Africa Allergy Immunotherapy Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 108 Middle East & Africa Allergy Immunotherapy Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
- Table 109 Middle East & Africa Allergy Immunotherapy Market Outlook, By Online Pharmacy (2021-2030) ($MN)
- Table 110 Middle East & Africa Allergy Immunotherapy Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
- Table 111 Middle East & Africa Allergy Immunotherapy Market Outlook, By End User (2021-2030) ($MN)
- Table 112 Middle East & Africa Allergy Immunotherapy Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 113 Middle East & Africa Allergy Immunotherapy Market Outlook, By Clinics (2021-2030) ($MN)
- Table 114 Middle East & Africa Allergy Immunotherapy Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
According to Stratistics MRC, the Global Allergy Immunotherapy Market is accounted for $2.67 billion in 2023 and is expected to reach $5.77 billion by 2030 growing at a CAGR of 11.6% during the forecast period. Allergy immunotherapy, also known as allergy shots or desensitization, is a treatment for allergies like pollen allergies, asthma, and food allergies. It works by gradually exposing the immune system to increasing amounts of allergens, retraining it to not overreact, and causing allergy symptoms. Unlike medications that just manage symptoms, immunotherapy offers the potential for a long-term solution or even a cure, making it a promising approach for those seeking relief from chronic allergies, thereby improving patient quality of life and reducing reliance on symptomatic medications.
According to the estimates of the American Academy of Allergy Asthma & Immunology, nearly 7.8% of the American population aged above 18 develops allergic rhinitis.
Market Dynamics:
Driver:
Rising prevalence of allergies
As more people develop allergies like asthma, hay fever, and food sensitivities, the demand for long-term solutions beyond just managing symptoms grows. Allergy immunotherapy offers a unique approach by gradually desensitizing the immune system to allergens, potentially curing allergies altogether. This increased need for a permanent solution, coupled with a growing population of allergy sufferers, creates a significant market opportunity for companies developing and delivering immunotherapy treatments.
Restraint:
Cost of treatment
Expenses associated with allergen extracts, physician visits, and monitoring for adverse reactions can be substantial. This financial burden may limit access to immunotherapy for some patients, particularly those without adequate financial resources. Also, the long-term nature of treatment and the need for continued follow-up appointments contribute to the overall cost, making it a barrier for individuals seeking this potentially beneficial therapy.
Opportunity:
Increasing focus on personalized medicine
The growing focus on personalized medicine unlocks a key opportunity for the Allergy Immunotherapy Market. By tailoring treatment plans to individual patients' specific allergies (considering factors like triggers, age, and medical history), personalized immunotherapy offers the potential for increased efficacy and improved safety. This targeted approach could make immunotherapy more attractive to a wider patient pool that might have been hesitant due to concerns about effectiveness or side effects, ultimately leading to significant market expansion.
Threat:
Alternative treatment options
Pharmacotherapy like antihistamines and corticosteroids, along with avoidance measures, compete with immunotherapy. These alternatives may be preferred by patients and healthcare providers due to convenience and perceived safety. This threatens market penetration and adoption rates of immunotherapy, potentially impacting revenue streams for providers and limiting the market's overall growth potential.
Covid-19 Impact
Initially, concerns about potential interactions and limited healthcare access caused disruptions, like delays in treatment initiation and a shift towards favoured sublingual immunotherapy methods (administered under the tongue) to minimize contact. However, the pandemic also highlighted the importance of managing chronic conditions like allergies, potentially leading to a future increase in demand for long-term solutions like immunotherapy.
The food allergy segment is expected to be the largest during the forecast period
The food allergy segment is estimated to hold the largest share. Immunotherapy for food allergies involves gradually exposing the body to increasing amounts of the allergenic food, with the goal of desensitizing the immune system and reducing the severity of allergic reactions. This targeted approach offers a potential cure for food allergies, as opposed to just managing symptoms, making it an attractive option for many patients. As food allergies become more prevalent, the segment is expected to see significant growth.
The retail pharmacy segment is expected to have the highest CAGR during the forecast period
The retail pharmacy segment is anticipated to have lucrative growth during the forecast period. Retail pharmacies stock a variety of allergen extracts, medications, and supplies necessary for immunotherapy treatments. Pharmacists at retail pharmacies provide counselling, education, and support to patients undergoing immunotherapy, ensuring proper administration, monitoring for adverse reactions, and optimizing treatment adherence. With their widespread presence and accessibility, retail pharmacies play a crucial role in expanding patient access to allergy immunotherapy and improving overall patient outcomes and satisfaction.
Region with largest share:
Asia Pacific commanded the largest market share during the extrapolated period owing to growing prevalence of allergies, increasing disposable income, and a strong presence of major pharmaceutical companies in developing Asian markets. These companies are investing in advancements like sublingual immunotherapy and improved allergen standardization, making the treatment more accessible and efficient. This, coupled with rising awareness about allergy management, positions the Asia Pacific region as a major growth engine for the Allergy Immunotherapy Market.
Region with highest CAGR:
North America is expected to witness profitable growth over the projection period, owing to high prevalence of allergies, strong public awareness about immunotherapy as a treatment option, and a robust healthcare infrastructure that facilitates access. Moreover, North America serves as a hotbed for research and development in allergy immunotherapy, constantly innovating and introducing novel treatment methods.
Key players in the market
Some of the key players in the Allergy Immunotherapy Market include ALK Abello, Allergy Therapeutics, Stallergenes Greer, Mylan N.V., Arrayit Corporation, Merck KGaA, Biomay AG, HollisterStier Allergy, HAL Allergy Group, ASIT Biotech, LETIPharma, Dermapharm Holding SE, Carcassia, Anergis, DVB Technologies SA, Adamis Pharmaceuticals Corporation.
Key Developments:
In July 2022, Stallergenes Greer, a global healthcare company that specializes in allergen immunotherapy (AIT), announced the positive data related to the significant benefit of sublingual liquid allergen immunotherapy treatment (AIT) on the onset and worsening of asthma in patients with allergic rhinitis
In April 2021, ALK initiated a clinical trial to study the safety and efficacy of sublingual immunotherapy tablets in children and adolescents suffering from allergic rhinitis induced by birch pollen.
Types Covered:
- Sublingual Immunotherapy
- Subcutaneous Immunotherapy
- Specific Immunotherapy
Allergy Types Covered:
- Allergic Asthma
- Allergic Rhinitis
- Atopic Dermatitis
- Food Allergy
- Other Allergy Types
Distribution Channels Covered:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
End Users Covered:
- Hospitals
- Clinics
- Diagnostic Centers
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Allergy Immunotherapy Market, By Type
- 5.1 Introduction
- 5.2 Sublingual Immunotherapy
- 5.3 Subcutaneous Immunotherapy
- 5.4 Specific Immunotherapy
6 Global Allergy Immunotherapy Market, By Allergy Type
- 6.1 Introduction
- 6.2 Allergic Asthma
- 6.3 Allergic Rhinitis
- 6.4 Atopic Dermatitis
- 6.5 Food Allergy
- 6.6 Other Allergy Types
7 Global Allergy Immunotherapy Market, By Distribution Channel
- 7.1 Introduction
- 7.2 Hospital Pharmacy
- 7.3 Online Pharmacy
- 7.4 Retail Pharmacy
8 Global Allergy Immunotherapy Market, By End User
- 8.1 Introduction
- 8.2 Hospitals
- 8.3 Clinics
- 8.4 Diagnostic Centers
9 Global Allergy Immunotherapy Market, By Geography
- 9.1 Introduction
- 9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
- 9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
- 9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa
10 Key Developments
- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies
11 Company Profiling
- 11.1 ALK Abello
- 11.2 Allergy Therapeutics
- 11.3 Stallergenes Greer
- 11.4 Mylan N.V.
- 11.5 Arrayit Corporation
- 11.6 Merck KGaA
- 11.7 Biomay AG
- 11.8 HollisterStier Allergy
- 11.9 HAL Allergy Group
- 11.10 ASIT Biotech
- 11.11 LETIPharma
- 11.12 Dermapharm Holding SE
- 11.13 Carcassia
- 11.14 Anergis
- 11.15 DVB Technologies SA
- 11.16 Adamis Pharmaceuticals Corporation
